This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mongero, L B Articles by Chabot, J A Search for Related Content PubMed PubMed Citation Articles by Mongero, L B Articles by Chabot, J A Social Bookmarking                         What's this?

Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy

Department of Surgery, Columbia-Presbyterian Medical Center, New York, LBMongero{at}aol.com

J R Beck

Department of Surgery, Columbia-Presbyterian Medical Center, New York

R M Kroslowitz

Department of Surgery, Columbia-Presbyterian Medical Center, New York

M Argenziano

Department of Surgery, Columbia-Presbyterian Medical Center, New York

J A Chabot

Department of Surgery, Columbia-Presbyterian Medical Center, New York

Perfusion of the peritoneal cavity with chemotherapy agents under hyperthermic conditions has been utilized by several investigators in the treatment of intra-abdominal malignancies. Based on the concept that hyperthermia may potentiate the cytotoxic effects of chemotherapeutic agents, we embarked on a clinical trial of two-stage peritoneal chemotherapy for patients with primary peritoneal mesothelioma, a neoplasm unresponsive to traditional systemic chemotherapeutic regimens. In stage I, patients underwent surgical debulking of gross disease and placement of an intraperitoneal infusion catheter, through which intraperitoneal chemotherapy was administered for four months. Stage II consisted of debulking of residual tumor, placement of two transabdominal perfusion cannulae and administration of high-dose intraperitoneal chemotherapy at 40°C using a simple, disposable perfusion circuit. Flow rates were maintained at 1 l/min, and inflow and outflow temperatures maintained at 42 and 40°C, respectively. To date, three patients have undergone both phases of the protocol, with no perioperative complications related to either hyperthermia or end-organ toxicity. One patient died of progressive disease after three months, and two patients are alive and well. One patient developed a small bowel anastomotic leak three weeks after operation. In summary, intraoperative hyperthermic peritoneal chemotherapy may play a role in novel approaches to the treatment of peritoneal malignancies previously unresponsive to traditional chemotherapeutic regimens.

Perfusion, Vol. 14, No. 2, 141-145 (1999)
DOI: 10.1177/026765919901400208


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?